Lupin Posts Record Q3 FY2026 Results, Prepares Generic Semaglutide Launch

Lupin reported a highly successful Q3 FY2026, marking the 14th consecutive quarter of YoY revenue growth, with total revenues reaching INR 7,168 crores, a 24% YoY increase, and a record EBITDA margin of 31.1%. The company is simultaneously undertaking a major business model shift, moving beyond its traditional focus on generic drugs, as it prepares to launch its generic semaglutide as part of a 'pivot year'.

Total revenues from operations for the quarter reached INR 7,168 crores, compared with INR 5,768 crores in Q3FY25. EBITDA, excluding Forex and other income, reached INR 2,210 crores, a 62% YoY increase. EBITDA margins hit 31.1% for the quarter, an increase of 681 basis points from 24.3% in the prior-year period. For the nine-month period, EBITDA margins stood at 29.8%.

The US business recorded its highest-ever sales at USD 350 million, achieving 46% YoY growth and 11% QoQ growth on a constant currency basis, driven by new product launches including Tolvaptan and strong base business growth. A major milestone was the US FDA approval for Pegfilgrastim, Lupin's first biosimilar for the US market, expected to launch shortly.

India region revenues grew 5.6% YoY, with the core prescription business growing 10.9% YoY in Q3 FY26 and 9.4% on a nine-month basis. The chronic segment now constitutes 67% of the portfolio, and key therapies like Respiratory and Cardiovascular grew at 1.6 times and 1.3 times IPM, respectively. Other Developed Markets (Europe, Canada, Australia) generated revenues of INR 812 crores, an 11% YoY growth. Emerging Markets delivered 42% YoY growth, led by Brazil (growing 99% YoY in local currency), Mexico, and the Philippines.

Gross margins reached 73.5%, up 420 basis points YoY, driven by a better product mix, lower share of in-licensed products, and cost efficiencies. R&D spend for the quarter was INR 535 crores (7.5% of sales), with almost 70% directed towards the complex portfolio. Management anticipates full-year R&D spend to remain in the 7.5% – 8.5% range.

The Injectables portfolio is targeted to deliver USD 100 million plus in revenue over the next three years, driven by biosimilars and 505(b)(2) filings, including the recent approval of Pegfilgrastim. The company is actively exploring capital allocation, noting the ability to borrow up to USD 1.5 billion, with M&A priorities focused on specialty assets in the US and Europe within the USD 250 million to USD 300 million range.

Lupin is poised to launch its generic version of semaglutide, the active ingredient in Novo Nordisk's popular diabetes and weight-loss drugs Wegovy and Ozempic, on 'Day 1' following patent expiry this week. The patent for semaglutide is set to expire around March 2026. Lupin's managing director anticipates prices could drop by 60-70% from current levels, making the treatment more affordable. The company expects significant market consolidation, with fewer than 10 out of roughly 50 branded generics likely to survive six months post-launch. Competitors like Dr. Reddy's Laboratories, Sun Pharma, and Cipla are also working on their own generic semaglutide versions, increasing competition.

As of March 14, 2026, Lupin's shares traded at a Price-to-Earnings ratio of approximately 22.7x, with a market capitalization around ₹1.07 trillion, compared to Cipla (P/E ~23.4x, Market Cap ~₹1.1T), Sun Pharmaceutical Industries (P/E ~39.3x, Market Cap ~₹432B), and Dr. Reddy's Laboratories (P/E ~19.6x, Market Cap ~₹108 billion). The overall Indian pharmaceutical sector is moving from basic generics towards complex generics, biosimilars, and specialty products, with innovation supported by government programs like Production Linked Incentive schemes.

Lupin's shift towards New Chemical Entity development involves high costs and a notable risk of failure. The upcoming launch of multiple semaglutide generics is expected to lead to intense price competition, potentially squeezing profit margins even with higher sales volumes. The market could see a 'slum of brands,' where strong competition limits profitability for most companies. Despite strong Q3 FY2026 results and revenue growth, especially in the US, geopolitical issues like the conflict in West Asia and related increases in logistics and insurance costs add operational challenges.

Recent positive developments include strong Q3 FY2026 earnings, a successful USFDA inspection at its Goa facility, and European Commission approval for its biosimilar ranibizumab, with the stock trading near its 52-week high.